GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Goodwill-to-Asset

Zydus Lifesciences (BOM:532321) Goodwill-to-Asset : 0.18 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Zydus Lifesciences's Goodwill for the quarter that ended in Mar. 2024 was ₹52,660 Mil. Zydus Lifesciences's Total Assets for the quarter that ended in Mar. 2024 was ₹292,808 Mil. Therefore, Zydus Lifesciences's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 was 0.18.


Zydus Lifesciences Goodwill-to-Asset Historical Data

The historical data trend for Zydus Lifesciences's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Goodwill-to-Asset Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.22 0.19 0.19 0.18

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 - 0.19 - 0.18

Competitive Comparison of Zydus Lifesciences's Goodwill-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Goodwill-to-Asset falls into.



Zydus Lifesciences Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Zydus Lifesciences's Goodwill to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Goodwill to Asset (A: Mar. 2024 )=Goodwill/Total Assets
=52660/292808
=0.18

Zydus Lifesciences's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Goodwill to Asset (Q: Mar. 2024 )=Goodwill/Total Assets
=52660/292808
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zydus Lifesciences  (BOM:532321) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Zydus Lifesciences Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines